{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-275595","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.578093+00:00","generated_at":"2026-05-29T04:35:12.463370+00:00","sec_items":["2.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acadia sells Rare Pediatric Disease PRV for $150M, one third to partner Neuren","bullets":["Closed sale of PRV for $150M on Dec 11, 2024, after HSR waiting period expired.","PRV awarded March 2023 from FDA approval of DAYBUE (trofinetide) for Rett syndrome.","One third of net proceeds payable to Neuren under July 2023 joint venture agreement.","Material terms of PRV Transfer Agreement previously disclosed in Q3 2024 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-275595","json":"https://secwatch.observer/filing/0001193125-24-275595.json","markdown":"https://secwatch.observer/filing/0001193125-24-275595.md","text":"https://secwatch.observer/filing/0001193125-24-275595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312524275595/0001193125-24-275595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312524275595/d841090d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:35:12.463370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}